Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1850 of 3008 results for all

  1. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

  2. The Space GlucoseControl system for managing blood‑glucose in critically ill patients in intensive care (MIB17)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care

  3. Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

    Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.

  4. Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)

    Evidence-based recommendations on quizartinib (Vanflyta) for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia in adults.

  5. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  6. Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)

    Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.

  7. Stakeholder registration: guidelines, quality standards and indicators

    How to register as a stakeholder to help us develop guidelines, quality standards and indicators.

  8. Stakeholder registration: guidelines, quality standards and indicators

    How to register as a stakeholder to help us develop guidelines, quality standards and indicators.

  9. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  10. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

  11. The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal (HTG566)

    Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal.

  12. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

  13. Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)

    Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.

  14. GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

  15. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  16. Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

    Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

  17. The hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability (MIB7)

    NICE has developed a Medtech Innovation Briefing (MIB) on the hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability

  18. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  19. ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)

    NICE has developed a medtech innovation briefing (MIB) on ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment

  20. Proov Confirm for ovulation confirmation (MIB322)

    NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .

  21. AposHealth for knee osteoarthritis (HTG671)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

  22. Photodynamic therapy for bile duct cancer (HTG82)

    Evidence-based recommendations on photodynamic therapy for bile duct cancer. This involves injecting a photosensitising agent into the body that is then activated by a small laser to destroy cancer cells and shrink the blockage.

  23. Injectable bulking agents for faecal incontinence (HTG135)

    Evidence-based recommendations on injectable bulking agents for faecal incontinence. This involves injecting a material into the muscles around the anus to bulk the sides of the sphincter.

  24. Cyanoacrylate instillation for occlusion of parotid sinuses (HTG20)

    Evidence-based recommendations on cyanoacrylate instillation for occlusion of parotid sinuses. This involves injecting a solution of lipiodiol and cyanoacrylate via the sinus into the parotid gland, sealing the sinus.

  25. Lower limb deep vein valve reconstruction for chronic deep venous incompetence (HTG141)

    Evidence-based recommendations on lower limb deep vein valve reconstruction for chronic deep venous incompetence. This involves restructuring valves in the deep veins of the legs by various surgical techniques, such as using stitches to repair the valve.

  26. Skin cancer (QS130)

    This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.

  27. Sexual health (QS178)

    This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.

  28. Osteoarthritis in over 16s (QS87)

    This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.

  29. Stroke in adults (QS2)

    This quality standard covers diagnosing and managing stroke in adults (over 16). It includes diagnosis, initial management, acute-phase care, rehabilitation and long-term support for people with stroke. It describes high-quality care in priority areas for improvement.

  30. Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)

    Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.

  31. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

  32. VIDAvision for lung volume analysis in emphysema (MIB148)

    NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .

  33. Developing a positive identity

    relationships . Relevant resources Visit the children's social care topic page for all NICE guidance and quality standards on children's...

  34. Supporting unaccompanied asylum-seeking children

    support. Relevant resources Visit the children's social care topic page for all NICE guidance and quality standards on children's social...

  35. Ensuring supported, coordinated transitions

    workers . Relevant resources Visit the children's social care topic page for all NICE guidance and quality standards on children's...

  36. Developing a culture of co-production

    commissioners . Relevant resources Visit the adults' social care topic page for all NICE guidance and quality standards on adults'...

  37. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  38. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

    Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.

  39. Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

    Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.

  40. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

  41. MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery (MIB323)

    NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .

  42. Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)

    NICE has developed a medtech innovation briefing (MIB) on Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children .

  43. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

  44. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

    NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .

  45. RT300 for spinal cord injury rehabilitation (MIB169)

    NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .

  46. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.

  47. Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.

  48. Eltrombopag for treating chronic immune thrombocytopenia (TA293)

    Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.

  49. Head injury (QS74)

    This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

  50. Corneal endothelial transplantation (HTG195)

    Evidence-based recommendations on corneal endothelial transplantation. This involves replacing only the innermost layers of the cornea with a healthy section from a donor eye without disturbing the overall structure.